Molecular characterization of ring finger protein 11

Molecular Cancer Research

Volumn 3, Issue 8, 2005, Pages 453-461

  Connor, Michael K ^a   Azmi, Peter B ^a,b   Subramaniam, Venkateswaran ^a   Li, Hoaxia ^c   Seth, Arun ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Sunnybrook and Women's College Health Sciences Centre ^*

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHOPEPTIDE; PROTEIN; PROTEIN 14 3 3; PROTEIN KINASE B; RING FINGER PROTEIN 11; THREONINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL NUCLEUS; CYTOPLASM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

14-3-3 PROTEINS; AMINO ACID SEQUENCE; BINDING SITES; CARRIER PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CHROMONES; COMPUTATIONAL BIOLOGY; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, DOMINANT; GLUTATHIONE TRANSFERASE; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; MORPHOLINES; MUTATION; PEPTIDE MAPPING; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 24144465684     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0166     Document Type: Article

References (42)

1. Akiyama S. The mechanisms of the resistance to molecular targeting agents. Nippon Rinsho 2004;62:I297-304.
2. Nishio K. Resistance to target-based therapy and its circumvention. Nippon Rinsho 2004;62:1343-7.
3. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
4. Seki N, Hattori A, Hayashi A, et al. Cloning and expression profile of mouse and human genes, Rnf11/RNF11, encoding a novel RING-H2 finger protein, Biochim Biophys Acta 1999;1489:421-7.
5. Subramaniam V, Li H, Wong M, et al. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 2003;89:1538-44.
6. Connor MK, Seth A. A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s. Oncogene 2004; 23:2089-95.
7. Flores SY, Debonneville C, Staub O. The role of Nedd4/Nedd4-like dependant ubiquitylation in epithelial transport processes. Pflugers Arch 2003;446:334-8.
8. Komuro A, Imamura T, Saitoh M, et al. Negative regulation of transforming growth factor-β (TGF-β) signaling by WW domain-containing protein 1 (WWP1). Oncogene 2004;23:6914-23.
9. Kitching R, Wong MJ, Koehler D, et al. The RINGH2 protein RNF11 is differentially expressed in breast tumours and interacts with HECT-type E3 ligases. Biochim Biophys Acta 2003;1639:104-12.
10. Li H, Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 2004;23:1801-8.
11. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF β receptor for degradation. Mol Cell 2000;6:1365-75.
12. Matthews JM, Sunde M. Zinc fingers-folds for many occasions. IUBMB Life 2002;54:351-5.
13. Ulrich HD. Protein-protein interactions within an E2-RING finger complex, implications for ubiquitin-dependent DNA damage repair. J Biol Chem 2003; 278:7051-8.
14. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.
15. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three akts. Genes Dev 1999;13:2905-27.
16. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42.
17. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60.
18. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
19. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase akt. Science 1997; 278:687-9.
20. Wilker E, Yaffe MB. 14-3-3 Proteins - a focus on cancer and human disease. J Mol Cell Cardiol 2004;37:633-42.
21. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:6049-54.
22. Yaffe MB. How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 2002;513:53-7.
23. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3:931-43.
24. Aitken A, Baxter H, Dubois T, et al. Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans 2002;30:351-60.
25. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
26. Baldin V. 14-3-3 proteins and growth control. Prog Cell Cycle Res 2000;4:49-60.
27. Abe T, Takagi N, Nakano M, Furuya M, Takeo S. Altered bad localization and interaction between bad and bcl-xL in the hippocampus after transient global ischemia. Brain Res 2004;1009:159-68.
28. (Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003;14:201-13.
29. Dikic I, Szymkiewicz I, Soubeyran P. Cbl signaling networks in the regulation of cell function. Cell Mol Life Sci 2003;60:1805-27.
30. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 2004;21:7-17.
31. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-16.
32. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
33. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
34. Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol 2003;13:5-14.
35. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7.
36. Lutz M, Knaus P. Integration of the TGF-β pathway into the cellular signalling network. Cell Signal 2002;14:977-88.
37. Mehra A, Wrana JL. TGF-β and the smad signal transduction pathway. Biochem Cell Biol 2002;80:605-22.
38. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major smad pathways in TGF-β superfamily signalling. Genes Cells 2002;7:1191-204.
39. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-β signaling and its roles in progression of tumors. Cancer Sci 2003;94:230-4.
40. Donovan J, Slingerland J. Transforming growth factor-β and breast cancer: cell cycle arrest by transforming growth factor-β and its disruption in cancer. Breast Cancer Res 2000;2:116-24.
41. Mentelone G, Pallone F, MacDonald T. Smad7 in TGFβ-mediated negative regulation of gut inflammation. Trends Immunol 2004;25:513-7.
42. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.